UREMIC VASCULOPATHY MODEL USING ENDOTHELIAL CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS AND UREMIC COMPLEX, AND USE THEREOF

摘要

The present invention relates to a model of uremic vasculopathy and uses of same. More specifically, the present invention relates to: a medium composition for producing an endothelial cell model of uremic vasculopathy, using a uremic complex that comprises urea and uric acid and may further comprise indoxyl sulfate, creatinine, or advanced glycation end products (AGEs); a preparation method for an endothelial cell model of uremic vasculopathy, comprising the step of treating endothelial cells with the uremic complex; an endothelial cell model of uremic vasculopathy, prepared by the preparation method; screening and toxicity testing methods, using the model, for agents that inhibit or treat uremic vasculopathy. The uremic complex comprising urea and uric acid of the present invention, merely by using said uremic toxins among other various kinds of uremic toxins, can enable creating a uremic environment in endothelial cells conveniently in a manner similar to when using the blood serum of a patient with chronic kidney disease. In addition, the uremic complex of the present invention, when used for preparing an endothelial cell model of uremic angiopathy, can produce an endothelial cell model capable of reflecting various symptoms of uremic angiopathy. Furthermore, by using endothelial cells differentiated from induced pluripotent stem cells when preparing the endothelial cell model of uremic vasculopathy, it is possible to produce an endothelial cell model of uremic vasculopathy with genetic characteristics reflected therein, which can be beneficially used in personalized drug screening for the treatment of patients with uremic vasculopathy, the development of new drugs, toxicity testing, and the like.